ABVC BioPharma (ABVC) News Today → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free ABVC Stock Alerts $1.42 -0.17 (-10.69%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineABVC BioPharma, Inc. (ABVC)finance.yahoo.com - April 26 at 11:08 AMShort Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Decreases By 59.6%americanbankingnews.com - April 26 at 1:30 AMABVC BioPharma inks licensing deal for cancer druginvesting.com - April 18 at 10:23 PMABVC BioPharma, Inc.: AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Sharefinanznachrichten.de - April 18 at 12:22 PMAiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Shareglobenewswire.com - April 18 at 9:25 AMABVC BioPharma Enters Licensing Agreement With OncoX For Commercialization Of BLEX 404markets.businessinsider.com - April 17 at 12:49 PMABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50Mfinance.yahoo.com - April 17 at 12:49 PMABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50Mglobenewswire.com - April 17 at 9:00 AMABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50Mglobenewswire.com - April 10 at 8:30 AMABVC BioPharma, Inc.: ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60Mfinanznachrichten.de - March 28 at 5:46 PMWhy ABVC BioPharma Stock Is Up Todaymsn.com - March 27 at 9:47 AMABVC Announces Global Licensing Deal With ForSeeCon Eye For Vitargusmarkets.businessinsider.com - March 26 at 12:22 PMABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60Mglobenewswire.com - March 26 at 8:30 AMAiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollarsfinance.yahoo.com - March 21 at 6:57 PMABVC BioPharma, Inc. (ABVC) Interactive Stock Chart - Yahoo Financeca.finance.yahoo.com - March 19 at 5:08 PMABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazineglobenewswire.com - March 19 at 8:30 AMABVC BioPharma, Inc.: ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Updatefinanznachrichten.de - March 14 at 12:45 PMABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Updateglobenewswire.com - March 14 at 9:30 AMABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollarsfinance.yahoo.com - February 27 at 12:50 PMABVC BioPharma, Inc.: ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenuesfinanznachrichten.de - February 15 at 1:58 PMABVC Signes Agreement To License Its 'Know-How' To SPImarkets.businessinsider.com - February 15 at 1:58 PMABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenuesfinance.yahoo.com - February 15 at 8:57 AMABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenuesglobenewswire.com - February 15 at 8:30 AMABVC BioPharma, Inc.: ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)finanznachrichten.de - February 12 at 2:51 PMABVC BioPharma Receives Australian Patent For PDC-1421 For Treatment Of MDDmarkets.businessinsider.com - February 12 at 2:51 PMABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)finance.yahoo.com - February 12 at 9:50 AMABVC BioPharma Conducts Private Equity and Warrants Salemsn.com - February 9 at 7:42 AMABVC BioPharma Expands Footprint with Strategic Land Acquisitionsmsn.com - February 9 at 7:42 AMLooking Into ABVC BioPharma's Recent Short Interestbenzinga.com - January 25 at 6:26 PMABVC BioPharma files to sell 10.4M shares for holdersmsn.com - January 12 at 6:25 PMWhy Is Plant-Based Medications-Focused ABVC BioPharma Stock Trading Higher Today?msn.com - January 3 at 3:50 PMABVC BioPharma Reports Milestone Payment From From AiBtl BioPharma; AiBtl Becomes Subsidiarymarkets.businessinsider.com - January 3 at 10:49 AMABVC BioPharma Shares Jump 73% After Milestone Paymentmarketwatch.com - January 3 at 10:49 AMABVC Biopharma and unit receive $460M as first milestone payment; shares jumpmsn.com - January 3 at 10:49 AMABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Studyfinance.yahoo.com - December 7 at 10:20 AMABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trialsfinance.yahoo.com - December 5 at 8:48 AMABVC BioPharma, Inc.: ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Marketfinanznachrichten.de - November 21 at 1:32 PMABVC BioPharma Shares Rise 11% After U.S. Patent for ADHD Treatmentmarketwatch.com - November 21 at 1:32 PMABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Marketfinance.yahoo.com - November 21 at 1:32 PMABVC BioPharma Enters Into Global LIcensing Agreement With AiBtlmarkets.businessinsider.com - November 16 at 4:53 PMABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200Mfinance.yahoo.com - November 16 at 11:52 AMABVC BioPharma, Inc.: ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Resultsfinanznachrichten.de - November 15 at 12:13 PMABVC BioPharma GAAP EPS of -$0.82, revenue of $0.02Mmsn.com - November 15 at 12:13 PMABVC BioPharma Reports Third Quarter 2023 Financial and Operational Resultsfinance.yahoo.com - November 15 at 12:13 PMWhat's Going On With ABVC Biopharma Stock Friday?benzinga.com - October 27 at 1:35 PMHealth Care Down Amid Mixed Earnings -- Health Care Roundupmarketwatch.com - October 26 at 7:25 PMWhat In The World Is Going On With ABVC BioPharma Stock?benzinga.com - October 26 at 2:25 PMABVC shares jump after signing licensing deal for CNS drugsmsn.com - October 26 at 2:25 PMABVC Shares More than Triple on Licensing Dealmarketwatch.com - October 26 at 9:25 AMABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Millionfinance.yahoo.com - October 26 at 9:25 AM Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon… Click For My #1 FREE Crypto for 2024 ABVC Media Mentions By Week ABVC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABVC News Sentiment▼0.760.32▲Average Medical News Sentiment ABVC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABVC Articles This Week▼31▲ABVC Articles Average Week Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cocrystal Pharma News Today NeuroBo Pharmaceuticals News Today Aytu BioPharma News Today Pieris Pharmaceuticals News Today Talphera News Today Addex Therapeutics News Today Flora Growth News Today Avalo Therapeutics News Today VBI Vaccines News Today Vaxxinity News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABVC) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
